
NanoString Showcases Groundbreaking Body of Research at the 2018 Annual Meeting of the American Association for Cancer Research
“We’re proud of the extent to which our technologies are being showcased at AACR this year, and we are excited about the opportunities for growth as we extend our leadership in biomarker development and precision oncology,” said
More than 50 abstracts using NanoString’s technologies will be presented at AACR, including applications such as gene expression profiling in cancer and immuno-therapy using
In addition,
Speakers will include:
Joseph Beechem Ph.D.,
Below are a subset of abstracts that best illustrate the unique capabilities of NanoString’s technology platform. A complete list of 51
Digital Spatial Profiling
Title: Highly multiplexed analysis of immune cell subsets in non-small cell lung cancer: validation of protein and RNA analysis by the NanoString DSP platform
Date/Time:
Author:
Poster #/Location: 2089/Poster Section 4, Board 4
Hyperlink: Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/1925
Digital Spatial Profiling (DSP) shows high section to section reproducibility and correlation with flow cytometry and immunohistochemistry.
Title: Digital spatial profiling platform allows for spatially-resolved, high-plex quantification of mRNA distribution and abundance on FFPE and fresh frozen tissue sections
Date/Time:
Author:
Poster #/Location: 3434/Section 18, Board 16
Hyperlink: Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7119
Digital Spatial Profiling can be used to obtain high-plex, spatial mRNA expression data (10’s to 100’s of genes) and protein expression data on FFPE and fresh frozen tissue sections.
Title: High-plex immune marker spatial profiling quantitation by NanoString® Digital Spatial Profiling technology and quantitative immunofluorescence
Date/Time:
Author:
Poster #/Location: 3621/Section 25, Board 29
Hyperlink: Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/2962
Digital Spatial Profiling shows promise in a pilot study of 30 spatially resolved protein immune markers for prognostic significance in a EGFR TKI treated NSCLC cohort as well as an ITx treated Melanoma cohort, and high concordance with AQUA. A Quantitative Immunofluoresence Assay (AQUA™) is a method for quantifying proteins through immunofluorescence.
Title: Validation of Digital Spatial Profiling of Key Immuno-Oncology Targets for Mouse FFPE Preclinical Models
Date/Time:
Author:
Poster #/Location: 3858/Section 36, Board 1
Hyperlink: Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/3493
Digital Spatial Profiling allows for the multiplexing of 10s to 100s of proteins, and
PlexSet Abstracts
Title: Digital Gene Expression of up to 96 Targets in 96 Samples for Cell Line Screening with nCounter® PlexSet
Date/Time:
Author:
Poster #/Location: 2342/Section 16, Board 3
Hyperlink: Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7033
Title: Cross-Comparison of Targeted Gene Expression Technologies for Patient Stratification
Date/Time:
Author: R. Venkatramanan et al, Covance
Poster #/Location: 3418/Section 16, Board 3
Hyperlink: Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7089
A comparison of PlexSet technology with various qPCR technologies on 96 colorectal FFPE samples. PlexSet, showed high correlation with RNA seq and robust reproducibility.
Gene Expression Profiling
Title: The tumor inflammation signature is predictive of anti-PD1 treatment benefit in the CERTIM pan-cancer cohort
Date/Time:
Author: D. Damotte, et al, Univ. Paris Descartes APHP and INSERM
Poster #/Location: 4546/Section 25, Board 1
Hyperlink: Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7648
The tumor inflammation signature (TIS) and other gene expression signatures, simultaneously analyzed using the IO 360 panel, predict clinical benefit of anti-PD1 treatment (nivolumab and pembrolizumab) in ‘real life’ patients with various cancer types, including NSCLC.
Title: Infiltrating immune cells in breast cancer subtypes
Date/Time:
Author:
Poster #/Location: 5698/Section 32, Board 4
Hyperlink: Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7977
Demonstrates the value of combining PAM50 subtype distribution with tumor immune profiling to identify biologically distinct patient populations; the combination of these signatures could be applied to the development of specific immunotherapeutics.
Title: The immune microenvironment in hormone receptor-positive breast cancer and treatment outcome following preoperative chemotherapy plus bevacizumab
Date/Time:
Author: A. Waks et al,
Poster #/Location: 4565/Section 26, Board 1
Hyperlink: Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7859
HR+/HER2- breast tumors with higher levels of tumor immune activity have a more favorable response to chemo plus bevacizumab. Deeper analysis into
Title: Prognostic gene signature use in checkpoint inhibitor monotherapy for melanoma
Date/Time:
Author: M. Capone et al, A. Waks et al, Istituto Nazionale Tumori IRCCS Fondazione
Poster #/Location: 558/Section 25, Board 1
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/2941
The NanoString IO 360 Panel is used to characterize tumor and PMBC samples from patients with metastatic melanoma treated with either ipilimumab or pembrolizumab to characterize local and peripheral patterns of gene expression associated with clinical benefit of therapy.
Title: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms
Date/Time:
Author: R. Novosiadly et al,
Poster #/Location: 4549/Section 25, Board 4
Pemetrexed promotes intra–tumor T cell–mediated immune response through immunogenic tumor cell death and increased activation and metabolic fitness of T cells, leading to an enhanced anti–tumor efficacy in combination with a PD–L1 antibody as shown by using
Title: Comprehensive immune and molecular analysis of two metastatic melanoma patients treated with a personal neoantigen vaccine, NEO-PV-01, in combination with anti-PD1: A case study
Date/Time:
Author: A. Naing, et al, MD Anderson and Neon Therapeutics
Poster #/Location: LB-147/Section 43, Board 14
Comprehensive immune profiling of two metastatic melanoma patients treated with a NEO-PC-01 in combination with nivolumab including deep immune profiling using NanoString’s Tumor Inflammation Signature and other IO signatures.
Abstract # |
Title | Hyperlink |
LB-147 |
Comprehensive immune and molecular analysis of two metastatic melanoma patients treated with a personal neoantigen vaccine, NEO-PV-01, in combination with anti-PD1: A case study |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/10469 |
LB-394 |
Profiling of endogenous circular RNA molecules in formalin-fixed paraffin-embedded tissues from patients with B-cell malignancies using an enzyme-free digital counting method |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/10695 |
NG06 |
The clinico-genomics of localized, non-indolent prostate cancer: the CPC-GENE experience |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/10887 |
558 |
Prognostic gene signature use in checkpoint inhibitor monotherapy for melanoma |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/2941 |
613 |
X4P-001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/8021 |
619 |
ALT-803 enhances antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by NEO-201 against human carcinoma cells |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/8028 |
634 |
SOX11 is a potential clinical marker for hormone receptor negative ductal carcinoma in situ |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/6349 |
982 |
Pharmacological DNA-PK inhibition induces ATM/p53 dependent premature senescence with immunomodulatory phenotype in irradiated cancer cells |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/9520 |
1020 |
Characterization of the immune landscape and analysis of tumor response after anti-PD-1 blockade in a 3D ex vivo system of non-small lung cancer |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/1844 |
1038 |
Xenograft-associated B cell lymphoproliferative disease as a surrogate model to study Epstein-Barr virus (EBV) driven lymphoma of the elderly |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/4969 |
1053 |
Highly characterized patient-derived PDX breast cancer collection for preclinical efficacy studies |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/4984 |
1361 |
Micro RNA-200C is one of the important Fanconi Anemia (FA) pathway downstream regulators in lung cancer |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/6297 |
1548 |
Genetic biomarkers predict clinical response and survival in myelodysplasia |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/2737 |
1584 |
Comparison of circulating tumor cell (CTC) capture/identification methods and NanoString evaluation of gene expression in CTCs and cell-free circulating tumor mRNA (cctmRNA) in patients with metastatic lung cancer |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/2667 |
1609 |
Simple and rapid high-plex analysis of RNA and protein from low-frequency sorted T cells |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/6417 |
1684 |
Selective SIRPa blockade potentiates dendritic cell antigen cross-presentation and triggers memory T-cell antitumor responses |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7704 |
1767 |
Synergy between intratumoral immunotoxin and systemic anti-CTLA-4 promotes massive inflammation and leads to complete regression of tumors in mice |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/8453 |
1981 |
Pan-cancer pathways gene expression profiling in mantle cell lymphoma reveals upregulation of DNA damage repair genes in ibrutinib-resistant tumor |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/5717 |
1985 |
Upregulation of miR-328 contributes to ovarian cancer stem cell maintenance by downregulating DDB2 |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/6165 |
2081 |
Empowering rare disease cohort biomarker discovery via comparative assessments of gene expression analysis platforms for FFPE pediatric brain tumor specimens |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/4193 |
2089 |
Highly multiplexed analysis of immune cell subsets in non-small cell lung cancer: validation of protein and RNA analysis by the Nanostring Digital Spatial Profiling (DSP) platform |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/1925 |
2342 |
Digital gene expression of up to 96 targets in 96 samples for cell line screening with nCounter® PlexSet™ |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7033 |
2555 |
Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7454 |
2982 |
Somatic TP53 mutations alter the immune microenvironment after chemotherapy in breast cancer |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/4162 |
3141 |
Immune gene expression and prognosis in localized clear cell (cc) renal cell carcinoma (RCC) |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/1618 |
3145 |
Characterization of novel immune checkpoint receptors within the breast cancer tumor microenvironment |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/1622 |
3397 |
Clinical significance of 3q amplification in squamous cell carcinoma of lung |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7067 |
3418 |
Cross-Comparison of Targeted Gene Expression Technologies for Patient Stratification |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7089 |
3425 |
Exome-sequencing derived mutations of endocrine treated ER-positive early breast cancer |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7110 |
3434 |
Digital spatial profiling platform allows for spatially resolved, high-plex quantification of mRNA distribution and abundance on FFPE and fresh frozen tissue sections |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7119 |
3497 |
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/8884 |
3593 |
Noncoding RNAs in early detection of radiation-induced late pulmonary effects |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/2860 |
3607 |
Quantitative dimensions of the PAM50 in breast tumors are prognostic and predict paclitaxel response |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/2899 |
3621 |
High-plex immune marker spatial profiling quantitation by NanoString Digital Spatial Profiling technology and quantitative immunofluorescence |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/2962 |
3682 |
Expression levels of genes in primary melanoma associated with clinically meaningful characteristics |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/6389 |
3692 |
PRECISION (Profiling Early Breast Cancer for radiotherapy Omission): An ongoing phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cancer |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/6399 |
3700 |
A window into human tumor progenitor cell subsets: Functionalizing a novel platform, the micropallet array, for molecular evaluation of single adherent cells with defined cell surface phenotype |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/6377 |
3858 |
Validation of digital spatial profiling of key immuno-oncology targets for mouse FFPE preclinical models |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/3493 |
3937 |
Differential alteration of IL-8 in liver cancer stem cell enrichment in response to PI3K/Akt/mTOR inhibitors and sorafenib |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/6762 |
3998 |
Integrative molecular analysis uncovers key molecules and signaling pathways regulated by RKIP in gastrointestinal stromal tumors (GISTs) |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/4543 |
4213 |
Molecular biomarker study of programmed death receptor ligand 1 (PD-L1) in Korean patients with lung adenocarcinoma |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/5416 |
4217 |
Prognostic gene expression signatures of immune responses in the colon cancer microenvironment |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/5420 |
4437 |
Down-modulation of ADAR1-mediated GLI1 editing alters extracellular and immune response genes in multiple myeloma |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/2269 |
4525 |
Cancer/testis antigens: A biomarker panel for prostate cancer screening |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/2736 |
4546 |
The tumor inflammation signature is predictive of anti-PD1 treatment benefit in the CERTIM pan-cancer cohort |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7648 |
4549 |
Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7651 |
4564 |
The immune microenvironment in hormone receptor-positive breast cancer and treatment outcome following preoperative chemotherapy plus bevacizumab |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7859 |
4707 |
Pelareorep promotes the expression of a chemokine signature that predicts response to immunotherapy |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/8181 |
4965 |
Entinostat transforms the suppressive tumor microenvironment of breast cancer and promotes survival and anti-responses when combined with checkpoint inhibition |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/3695 |
5402 |
A panel of miRNAs for diagnosis of wild-type thyroid nodules with pre-surgical indeterminate cytology |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/5923 |
5698 |
Infiltrating immune cells in breast cancer |
Opens in new windowhttp://www.abstractsonline.com/pp8/#!/4562/presentation/7977 |
About NanoString Technologies, Inc.
For more information, please visit Opens in new windowwww.nanostring.com.
Contact:
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768
Source: NanoString Technologies, Inc.